G-Cotrimoxazole400 mg+80 mg

G-Cotrimoxazole is a fixed-dose combination antibacterial (sulfamethoxazole and trimethoprim, also known as co-trimoxazole/SMX-TMP) that acts synergistically to sequentially block two steps in bacterial folic acid synthesis. Indications vary in the strength of supporting evidence:

FDA-Approved / Established Uses

• Urinary tract infections caused by susceptible strains of E. coli, Klebsiella, Proteus, and other susceptible organisms
• Acute otitis media in children (when caused by susceptible strains)
• Acute exacerbations of chronic bronchitis in adults
• Shigellosis (bacillary dysentery) caused by susceptible Shigella strains
• Traveler's diarrhea caused by susceptible strains of enterotoxigenic E. coli
• Pneumocystis jirovecii pneumonia (PCP) — both treatment and first-line prophylaxis, particularly in immunocompromised patients (e.g., HIV/AIDS, transplant recipients)

Guideline-Supported / Adjunct Uses

• Toxoplasmosis prophylaxis in selected immunocompromised patients (as part of guideline-based regimens)
• Nocardiosis, as part of combination or alternative therapy where guideline-supported

G-Cotrimoxazole should be used only for infections proven or strongly suspected to be caused by susceptible bacteria, as confirmed where possible by culture and susceptibility testing, to reduce the development of drug-resistant organisms.

Each tablet of Cotrimoxazole typically contains Sulfamethoxazole and Trimethoprim in a 5:1 ratio — commonly available as a standard-strength tablet (400 mg sulfamethoxazole + 80 mg trimethoprim) and a double-strength (DS) tablet (800 mg sulfamethoxazole + 160 mg trimethoprim). An oral suspension (typically 200 mg sulfamethoxazole + 40 mg trimethoprim per 5 mL) and an intravenous infusion formulation are also available. Strengths and available forms may vary by manufacturer.

G-Cotrimoxazole is a synthetic, fixed-dose combination antibacterial agent composed of sulfamethoxazole (a sulfonamide) and trimethoprim (a diaminopyrimidine), combined in a fixed ratio to produce a synergistic antibacterial effect broader than either component alone. G-Cotrimoxazole is available as oral tablets (standard and double-strength), an oral suspension, and an intravenous infusion for the treatment of susceptible bacterial infections and for prophylaxis of Pneumocystis jirovecii pneumonia.

Combination antibacterial (sulfonamide + folate-pathway inhibitor); also known as co-trimoxazole/SMX-TMP

Cotrimoxazole combines two antibacterial agents that block sequential steps in bacterial folic acid (tetrahydrofolate) synthesis. Sulfamethoxazole competitively inhibits dihydropteroate synthase, blocking incorporation of para-aminobenzoic acid (PABA) into dihydrofolic acid, while trimethoprim inhibits dihydrofolate reductase, blocking conversion of dihydrofolic acid to tetrahydrofolic acid. This sequential blockade produces a synergistic bactericidal effect against a broad range of gram-positive and gram-negative organisms, including many strains resistant to either agent alone.

Following oral administration, both components of Cotrimoxazole are well absorbed, achieving peak plasma concentrations within 1–4 hours. Both are widely distributed throughout body tissues and fluids, including sputum, middle-ear fluid, and cerebrospinal fluid. Sulfamethoxazole is more highly protein-bound and more extensively hepatically metabolized than trimethoprim. Both components are eliminated primarily by the kidneys, with elimination half-lives of approximately 8–12 hours in patients with normal renal function; dosage adjustment is required in renal impairment.

G-Cotrimoxazole tablets should be swallowed whole with a full glass of water; do not crush or chew double-strength tablets unless directed. The oral suspension should be shaken well before each use and measured with an accurate dosing device, not a household spoon. G-Cotrimoxazole may be taken with or without food, and taking it with food or a full glass of water can help reduce stomach upset. Adequate fluid intake should be maintained during treatment. If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next dose, in which case the missed dose should be skipped; doses should never be doubled.

The following are well-established, clinically significant interactions with G-Cotrimoxazole:

• Warfarin and other oral anticoagulants: G-Cotrimoxazole can significantly potentiate anticoagulant effect (via protein-binding displacement and metabolic inhibition), increasing bleeding risk; prothrombin time/INR should be monitored closely and dose adjusted if co-administered.
• ACE inhibitors, angiotensin receptor blockers, potassium-sparing diuretics, and other potassium-elevating drugs: Increased risk of significant hyperkalemia, particularly in elderly patients or those with renal impairment; monitor serum potassium.
• Methotrexate: G-Cotrimoxazole can displace methotrexate from protein binding and impair its renal clearance, increasing risk of methotrexate toxicity and additive bone-marrow suppression; avoid combination or monitor closely.
• Phenytoin: G-Cotrimoxazole inhibits hepatic metabolism of phenytoin, potentially increasing phenytoin levels and toxicity; monitor phenytoin levels if co-administered.
• Sulfonylureas (e.g., glyburide, glipizide): G-Cotrimoxazole can potentiate hypoglycemic effect, increasing risk of hypoglycemia; monitor blood glucose closely.
• Dofetilide and other QT-prolonging drugs: Increased risk of QT prolongation and cardiac arrhythmia; concurrent use of G-Cotrimoxazole with dofetilide is contraindicated by the dofetilide labeling.
• Cyclosporine: Risk of reversible deterioration in renal function when used with G-Cotrimoxazole, particularly in transplant patients; monitor renal function.

Always inform the physician or pharmacist of all other medicines being used before starting G-Cotrimoxazole.

Most adverse effects associated with G-Cotrimoxazole are mild to moderate, but some serious reactions require prompt medical attention.

Common

• Nausea, vomiting
• Loss of appetite
• Diarrhea
• Skin rash
• Headache

Less Common / Serious (see Precautions and Warnings for detail)

• Severe hypersensitivity reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis
• Blood disorders (agranulocytosis, aplastic anemia, thrombocytopenia, hemolytic anemia) with prolonged use
• Hyperkalemia, particularly in renal impairment or elderly patients
• Hepatotoxicity, including cholestatic jaundice and fulminant hepatic necrosis (rare)
• Photosensitivity reactions
• Clostridioides difficile-associated diarrhea/colitis

Pregnancy: G-Cotrimoxazole should generally be avoided during pregnancy, particularly during the first trimester (association with congenital malformations in some epidemiologic studies) and at term (risk of neonatal kernicterus). G-Cotrimoxazole should be used during pregnancy only if clearly needed, no safer alternative exists, and the potential benefit justifies the potential risk to the fetus. A physician must always be consulted before use in pregnancy, and G-Cotrimoxazole is contraindicated at term/near delivery (see Contraindications).

Lactation: Both components of G-Cotrimoxazole pass into breast milk. G-Cotrimoxazole should be avoided while breastfeeding a newborn or premature infant, or an infant with hyperbilirubinemia or glucose-6-phosphate dehydrogenase (G6PD) deficiency, due to the risk of kernicterus and hemolysis. Consult a physician before using G-Cotrimoxazole while breastfeeding.

Severe Skin/Hypersensitivity Reactions: G-Cotrimoxazole has been associated with rare but serious and potentially fatal hypersensitivity reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Discontinue G-Cotrimoxazole immediately at the first appearance of skin rash or any sign of hypersensitivity and seek medical attention.

Hyperkalemia: G-Cotrimoxazole can cause significant hyperkalemia, particularly in patients with renal impairment, the elderly, or those taking other potassium-elevating drugs; monitor serum potassium in at-risk patients.

Blood Dyscrasias: Prolonged or high-dose use of G-Cotrimoxazole can cause blood disorders including agranulocytosis, aplastic anemia, and thrombocytopenia due to folate antagonism; periodic blood counts are advised with extended therapy, and folinic acid supplementation may be considered if needed.

Hepatic and Renal Function: Use G-Cotrimoxazole with caution in patients with impaired hepatic or renal function; dose adjustment is required in renal impairment (see Dosage and Administration), and G-Cotrimoxazole is contraindicated in severe hepatic or renal impairment (see Contraindications).

Photosensitivity: G-Cotrimoxazole may increase sensitivity to sunlight; excessive sun/UV exposure should be avoided during treatment.

G6PD Deficiency: Hemolysis may occur in patients with glucose-6-phosphate dehydrogenase deficiency; use G-Cotrimoxazole with caution in this population.

Antibiotic stewardship: Take G-Cotrimoxazole exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice.

Overdose with G-Cotrimoxazole may cause nausea, vomiting, abdominal pain, dizziness, confusion, headache, and, in severe cases, bone-marrow suppression, jaundice, and crystalluria. If an overdose of G-Cotrimoxazole is suspected, seek immediate medical attention or contact a poison control center/emergency services right away. Treatment is general and supportive (e.g., gastric decontamination if appropriate, fluid support, and monitoring of blood counts and renal function); there is no specific antidote, though folinic acid may be used to counter bone-marrow toxicity under medical supervision.

Store G-Cotrimoxazole tablets/suspension at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not use beyond the expiry date printed on the pack.

Renal impairment: Dose reduction of G-Cotrimoxazole is required for creatinine clearance 15–30 mL/min; use is not recommended below 15 mL/min unless the patient is on dialysis and closely monitored by a physician (see Dosage and Administration).

Hepatic impairment: Use G-Cotrimoxazole with caution in mild hepatic impairment; it is contraindicated in severe hepatic damage (see Contraindications).

Elderly: Older adults, particularly those with renal impairment or on concurrent diuretics, are at increased risk of severe adverse reactions with G-Cotrimoxazole, including hyperkalemia and blood dyscrasias; use with caution and monitor closely.

G6PD deficiency: Increased risk of hemolytic anemia with G-Cotrimoxazole; use with caution (see Precautions and Warnings).

Treatment duration with G-Cotrimoxazole depends on the indication: typically 5 days for shigellosis and traveler's diarrhea, 10–14 days for urinary tract infections, and 14 days for acute exacerbations of chronic bronchitis. Treatment of Pneumocystis jirovecii pneumonia typically continues for 14–21 days, while prophylaxis against Pneumocystis jirovecii pneumonia may continue for extended periods (months to years) as directed by a physician based on the patient's underlying risk. The exact duration of G-Cotrimoxazole therapy should always follow the prescribing physician's instructions and should not be shortened or extended without medical advice.

Sulfonamide antibacterial combinations; folate-pathway inhibitor combinations

Cotrimoxazole combines sulfamethoxazole and trimethoprim, which sequentially inhibit two consecutive enzymes in the bacterial folic acid synthesis pathway. Sulfamethoxazole competitively inhibits dihydropteroate synthase, preventing bacterial synthesis of dihydrofolic acid from para-aminobenzoic acid, while trimethoprim inhibits bacterial dihydrofolate reductase, blocking the subsequent conversion of dihydrofolic acid to tetrahydrofolic acid (the active form required for nucleic acid synthesis). This dual, sequential blockade produces a synergistic bactericidal effect that is more potent and has a broader spectrum than either component used alone, and reduces the likelihood of resistance development compared with either agent given individually.

C (D at term)

G-Cotrimoxazole is approved for use in children 2 months of age and older for susceptible urinary tract infections, acute otitis media, shigellosis, and Pneumocystis jirovecii pneumonia treatment/prophylaxis, using weight-based dosing calculated on the trimethoprim component, as directed by a physician. G-Cotrimoxazole is contraindicated in infants younger than 2 months of age due to the risk of kernicterus and because safety and efficacy have not been established in this age group. Pediatric dosing of G-Cotrimoxazole must always be calculated by a physician based on the child's weight and the specific infection being treated.